NCT03489525: Phase 1: MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma (MEDI2228)

NCT03489525: Phase 1: MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma (MEDI2228)

The purpose of this study is to assess the safety, pharmacokinetics and tolerability, describe the dose-limiting toxicities (DLTs), and determine the maximum tolerated dose (MTD) or maximum administered dose (MAD [in the absence of establishing the MTD]) for single agent MEDI2228 in adult subjects with multiple myeloma who are either transplant ineligible or post autologous stem cell transplant and are relapsed/refractory

Sponsor

MedImmune LLC

Multiple Locations

International Study

---

Official Title: A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma

First Posted: April 5, 2018

https://clinicaltrials.gov/ct2/show/NCT03489525

---

Biological: Dose Escalation, MEDI2228, ADC (antibody drug conjugate)

Biological: Dose Expansion, MEDI2228, ADC (antibody drug conjugate)

---

Anti-BCMA ADC MEDI2228

Anti-BCMA/PBD ADC MEDI2228 (Code C150127)

ADC MEDI2228

Anti-BCMA ADC MEDI2228

Anti-BCMA/PBD ADC MEDI2228

Anti-BCMA/PBD MEDI2228

Antibody-drug Conjugate MEDI2228

MEDI 2228

MEDI-2228

MEDI2228

---

Locations

United States, Arizona

United States, Florida

United States, Massachusetts

United States, Michigan

United States, Minnesota

United States, North Carolina

United States, Virginia

Australia

Europe

Spain

Greece